Adapting reinsurance to relieve biotech bottleneck

  • Print
  • Connect
  • Email
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
By Bruce S. Pyenson | 01 June 2008

A pharmaceutical reinsurance mechanism could help fund high-cost research and minimize the market uncertainty that often impairs drug development efforts, thereby stimulating innovation. How would such a mechanism work? Bruce Pyenson explains the concept.

Read or print the article